CTRI/2022/07/044190进行中（未招募）4 期
A Multicenter, Open label Study to Assess Safety and Efficacy of Fixed Dose Combination of Cephalexin Extended Release and Clavulanate Potassium Tablets in Patients with Upper Respiratory Tract Infection and Uncomplicated Skin & Soft Tissue Infection. - NA
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •Inclusion Criteria for Upper Respiratory Tract Infection (URTI) Patients
- •1)Patients of either sex, aged 12 to 65 years (both inclusive), who have given written informed consent/assent to participate in the study. An additional written informed consent will be obtained from parent/legally acceptable representative (as applicable) in case assent is taken from patients aged <18 years
- •2)Patients with confirmed diagnosis of acute upper respiratory tract infection (pharyngitis, tonsillitis or pharyngotonsillitis) based on modified Centor score (McIsaac score) = 3 and positive for rapid antigen test (RADT) during the screening period.
- •Inclusion Criteria for Uncomplicated Skin & Soft Tissue Infection (uSSTI) Patients
- •1)Patients of either sex, aged 12 to 65 years (both inclusive), who have given written informed consent/assent to participate in the study. An additional written informed consent will be obtained from parent/legally acceptable representative (as applicable) in case assent is taken from patients aged <18 years.
- •2)Patients with confirmed diagnosis of uncomplicated skin and soft tissue infections (uSSTI) and culturable microbiological specimen, with an onset of infection = 7 days requiring antibiotic therapy. Acceptable clinical diagnosis of uSSTIs include: simple abscess, impetigo, furunculosis, carbuncles, cellulitis (area <10 cm2), erysipelas, folliculitis, paronychia, superficial wound infections (traumatic, post-surgical) etc.
- •3)Patients with at least three or more of the following local signs and symptoms of uSSTI accompanied with or without systemic features of infection such as pain/tenderness, purulent drainage/discharge, erythema with or without induration, swelling, fluctuance, heat/localized warmth, regional lymph node swelling or tenderness and/or extension of redness.
排除标准
- •Exclusion Criteria for Upper Respiratory Tract Infection Patients:
- •1)Patients with history of hypersensitivity to cephalexin, other cephalosporins, penicillins, clavulanate potassium or other beta-lactam class of antibiotics or any of the excipients of study formulation.
- •2)Patients with infection of the deep tissues of the upper respiratory tract (e.g. epiglottitis, retropharyngeal or buccal cellulitis or abscess of the retropharynx/ tonsil or peritonsillar area) or of the suprapharyngeal respiratory tract and its connecting structures (e.g. sinusitis, otitis media or orbital/periorbital cellulitis).
- •3)Patients with concurrent symptoms suggestive of viral etiology including conjunctivitis, coryza and cough; diffuse adenopathy or rash suggestive of mononucleosis; rash or arthropathy suggestive of scarlet fever.
- •4)Patients with history of rheumatic or valvular heart disease or glomerulonephritis.
- •5)Patients requiring hospitalization or parenteral antibiotic treatment.
- •6)Patients who have received antibiotic treatment for = 24 hours during the 72 hours prior to enrollment in the study (unless treatment failure was documented).
- •7)Patients with history of neoplasia or immunosuppression or on chronic immunosuppressive therapy or diagnosis of acquired immunodeficiency syndrome (AIDS).
- •8)Patients with significant disease(s) (such as uncontrolled metabolic disorders, cancer etc.) or disorder(s) other than the disease in consideration that in the opinion of the investigator may (i) put the patient at risk because of participation in the study or (ii) interfere with the study evaluations or (iii) cause concern regarding patient’s ability to participate in the study or (iv) needs an additional anti-microbial agent
- •9)Pregnant or breast feeding women or women of child-bearing potential not using medically acceptable methods of contraception or women with positive urine pregnancy test (UPT) at screening.
- •10)Patients unwilling or unable to comply with the study procedures
- •11)Patients who have participated in another investigational study in the past 3 months prior to enrollment in this study.
- •Exclusion Criteria for Uncomplicated Skin & Soft Tissue Infection (uSSTI) Patients:
- •1)Patients with history of hypersensitivity to cephalexin, other cephalosporins, penicillins or other beta-lactam class of antibiotics, clavulanate potassium or any of the excipients of study formulation.
- •2)Patients requiring hospitalization or parenteral antibiotic treatment.
- •3)Patients with complicated acute bacterial skin and skin structure infections (ABSSSI) as judged by the investigator or with chronic or underlying skin condition at the site of infection (e.g., a secondarily infected atopic dermatitis, eczema, acne vulgaris or burn wounds) or infections involving prosthetic materials (e.g., catheter tunnel infections, orthopedic instruments).
- •4)Patients who have received antibiotic treatment for = 24 hours during the 72 hours period prior to enrollment in the study (unless treatment failure was documented).
- •5)Patients with concomitant condition requiring non-study antibacterial therapy.
- •6)Patients with involvement of perianal area, facial cellulitis or cellulitis associated with animal or human bite (except insect bite).
- •7)Patients with skin and soft tissue infection with suspected or proven contiguous bone, nail bed or scalp involvement. <br/
研究者
相似试验
暂停
1 期
A multi-centre study of the safety, tolerability and effects of intravenously administered Cyclic Pyranopterin Monophosphate (cPMP) in patients with molybdenum cofactor deficiency type A.ACTRN12609000849291PMP(Vic) Pty Ltd10
招募中
1 期
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type IITuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia (FCD) Type IIMedDRA version: 20.0Level: LLTClassification code: 10070672Term: Focal cortical dysplasia Class: 10010331MedDRA version: 21.0Level: PTClassification code: 10080584Term: Tuberous sclerosis complex Class: 100000004850CTIS2023-506301-20-00Grin Therapeutics Inc.34
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisPsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-003046-87-PLAbbVie Deutschland GmbH & Co. KG2,200
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisEUCTR2016-003046-87-PTAbbVie Deutschland GmbH & Co. KG2,200
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisPsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-003046-87-SEAbbVie Deutschland GmbH & Co. KG2,200